The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus.
PD-1 agonist
biomarker
pathogenesis
systemic lupus erythematosus
targeted therapy
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
11
2022
accepted:
27
02
2023
medline:
28
3
2023
entrez:
27
3
2023
pubmed:
28
3
2023
Statut:
epublish
Résumé
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs. It is often called "immortal cancer" due to the difficulties in disease treatment. As the cornerstone of immune regulation, the programmed cell death protein 1 (PD-1) has been extensively studied in the context of chronic inflammation due to its ability of regulating immune response and immunosuppression. Recently, more and more studies on rheumatic immune related complications have also focused on PD-1 and proposed that the use of PD-1 agonist could inhibit the activation of lymphocytes and alleviate SLE disease activity. In this review, we summarized the role of PD-1 in SLE, implicating its potential application as a biomarker to predict SLE disease activity; we also proposed that the combination of PD-1 agonist and low-dose IL-2 may have better therapeutic efficacy, shining light on a new direction for developing specific treatment approaches.
Identifiants
pubmed: 36969198
doi: 10.3389/fimmu.2023.1111005
pmc: PMC10030866
doi:
Substances chimiques
Interleukin-2
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1111005Informations de copyright
Copyright © 2023 Wang, Chen, Liu, Zhou, Xu and Wu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:85-112
pubmed: 32871087
Front Immunol. 2019 Nov 08;10:2606
pubmed: 31781109
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
JCI Insight. 2021 Oct 22;6(20):
pubmed: 34491911
Ann Rheum Dis. 2019 Mar;78(3):365-371
pubmed: 30626657
J Clin Oncol. 2018 Jul 1;36(19):1905-1912
pubmed: 29746230
J Rheumatol. 2007 Apr;34(4):721-5
pubmed: 17343323
Arthritis Rheumatol. 2017 Feb;69(2):376-386
pubmed: 28130918
Ann Rheum Dis. 2018 Jan;77(1):104-110
pubmed: 28970217
Postepy Hig Med Dosw (Online). 2015 Apr 28;69:534-42
pubmed: 25983292
J Rheumatol. 2004 Oct;31(10):1934-40
pubmed: 15468356
Lancet. 2019 Jun 8;393(10188):2344-2358
pubmed: 31180031
Nat Rev Immunol. 2019 Oct;19(10):614-625
pubmed: 31201377
Int Immunol. 2007 Jul;19(7):813-24
pubmed: 17606980
Rheumatology (Oxford). 2008 Sep;47(9):1335-41
pubmed: 18650228
Ann Rheum Dis. 2018 Sep;77(9):1354-1361
pubmed: 29853448
Autoimmun Rev. 2021 Dec;20(12):102980
pubmed: 34718163
Eur J Neurol. 2016 Jan;23 Suppl 1:18-27
pubmed: 26563094
J Autoimmun. 2019 Aug;102:96-113
pubmed: 31130368
J Immunol. 2016 Mar 15;196(6):2431-7
pubmed: 26945088
Curr Opin Rheumatol. 2019 May;31(3):307-315
pubmed: 30920455
Immunol Rev. 2009 May;229(1):114-25
pubmed: 19426218
Biomaterials. 2022 Jun;285:121517
pubmed: 35504179
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362
pubmed: 33580222
Eur J Immunol. 2003 Nov;33(11):3117-26
pubmed: 14579280
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Science. 2019 May 10;364(6440):558-566
pubmed: 31000591
J Immunol. 2002 Nov 15;169(10):5538-45
pubmed: 12421930
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15569-74
pubmed: 16221763
AJNR Am J Neuroradiol. 2017 Sep;38(9):1672-1680
pubmed: 28428206
Rheumatology (Oxford). 2014 Jan;53(1):85-9
pubmed: 24067885
Arthritis Rheum. 2009 Jan;60(1):207-18
pubmed: 19116915
J Leukoc Biol. 2011 Apr;89(4):507-15
pubmed: 21097698
J Cell Biol. 2020 Jun 1;219(6):
pubmed: 32437509
Cytokine. 2011 Nov;56(2):231-8
pubmed: 21733718
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
Cancer Treat Rev. 2017 Jun;57:36-49
pubmed: 28550712
Curr Opin Immunol. 1999 Jun;11(3):294-300
pubmed: 10375557
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):
pubmed: 34272285
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
J Rheumatol. 2018 Jun;45(6):835-840
pubmed: 29419471
Immunity. 1999 Aug;11(2):141-51
pubmed: 10485649
Arthritis Res Ther. 2017 Mar 9;19(1):52
pubmed: 28274252
Immunity. 2019 Dec 17;51(6):1059-1073.e9
pubmed: 31757674
Clin Immunol. 2016 Aug;169:58-68
pubmed: 27237127
Cancers (Basel). 2022 Mar 15;14(6):
pubmed: 35326658
Nat Immunol. 2018 Jun;19(6):571-582
pubmed: 29760532
Sci Rep. 2012;2:295
pubmed: 22389764
Lupus Sci Med. 2022 Jun;9(1):
pubmed: 35738802
Clin Rheumatol. 2021 Jan;40(1):151-165
pubmed: 32542581
J Autoimmun. 2018 Dec;95:77-99
pubmed: 30174217
J Neuroimmunol. 1998 Aug 14;89(1-2):10-8
pubmed: 9726820
PLoS One. 2013 Jun 14;8(6):e65068
pubmed: 23799000
Clin Immunol. 2005 May;115(2):184-91
pubmed: 15885642
Arthritis Rheumatol. 2015 Apr;67(4):988-99
pubmed: 25581113
Rheumatology (Oxford). 2019 Dec 1;58(12):2188-2192
pubmed: 31180450
J Formos Med Assoc. 2021 Jan;120(1 Pt 1):48-59
pubmed: 32334916
Arthritis Res Ther. 2016 Feb 11;18:47
pubmed: 26867643
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141886
Nat Genet. 2002 Dec;32(4):666-9
pubmed: 12402038
Immunity. 2018 Aug 21;49(2):264-274.e4
pubmed: 30076099
Nat Immunol. 2022 Mar;23(3):399-410
pubmed: 35145298
J Exp Med. 2003 Jul 7;198(1):63-9
pubmed: 12847137
Nat Commun. 2018 May 1;9(1):1758
pubmed: 29717110
J Exp Med. 2003 May 5;197(9):1083-91
pubmed: 12719480
Int Arch Allergy Immunol. 2021;182(10):1008-1016
pubmed: 34375975
Front Immunol. 2022 Mar 09;13:773946
pubmed: 35356000
Immunity. 2019 Apr 16;50(4):907-923
pubmed: 30995506
J Immunol. 2006 Dec 15;177(12):8844-50
pubmed: 17142787
J Clin Invest. 2003 Nov;112(10):1506-20
pubmed: 14617752
Immunity. 2018 Aug 21;49(2):247-263.e7
pubmed: 30054205
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Nat Commun. 2020 Aug 10;11(1):3998
pubmed: 32778730
Cancer Immunol Res. 2021 Dec;9(12):1439-1450
pubmed: 34526323
Scand J Immunol. 2020 Jul;92(1):e12884
pubmed: 32243638
Trends Mol Med. 2021 Feb;27(2):152-171
pubmed: 33046407
Acta Pharmacol Sin. 2021 Jan;42(1):1-9
pubmed: 32152439
Lupus. 2015 Jan;24(1):82-9
pubmed: 25253568
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Am J Nephrol. 2017;46(5):371-379
pubmed: 29069649
J Autoimmun. 2016 Nov;74:94-105
pubmed: 27373904
Nat Rev Dis Primers. 2020 Jan 23;6(1):7
pubmed: 31974366
Trends Pharmacol Sci. 2018 Mar;39(3):307-325
pubmed: 29254698
J Exp Med. 2012 Jun 4;209(6):1201-17
pubmed: 22641383
Blood. 2005 Jan 1;105(1):13-21
pubmed: 15353480
Cell Mol Immunol. 2021 May;18(5):1336-1338
pubmed: 33067573
J Cancer. 2021 Mar 5;12(9):2735-2746
pubmed: 33854633
J Exp Med. 1991 Sep 1;174(3):561-9
pubmed: 1714933
Arthritis Rheumatol. 2019 Sep;71(9):1539-1544
pubmed: 30919595
J Autoimmun. 2019 Feb;97:1-9
pubmed: 30396745
Lupus. 2020 Jun;29(7):686-696
pubmed: 32264742
Blood. 2017 Apr 13;129(15):2186-2197
pubmed: 28151427
Arthritis Rheumatol. 2021 Jan;73(1):132-142
pubmed: 32720470
J Autoimmun. 2020 Jun;110:102374
pubmed: 31812331
J Immunol. 2015 May 1;194(9):4545-54
pubmed: 25810391
Semin Immunol. 2021 Feb;52:101480
pubmed: 34006473
Nat Immunol. 2013 Dec;14(12):1212-8
pubmed: 24240160
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Clin Exp Immunol. 2021 Oct;206(1):28-35
pubmed: 34240405
J Hepatol. 2006 Oct;45(4):468-72
pubmed: 16901572
Nat Med. 2016 Sep;22(9):991-3
pubmed: 27500725
J Immunol. 2009 Jun 1;182(11):6682-9
pubmed: 19454662